[HTML][HTML] Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters
S Moazemi, A Erle, Z Khurshid, S Lütje… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background Treatment with radiolabeled ligands to prostate-specific membrane antigen
(PSMA) is gaining importance in the treatment of patients with advanced prostate carcinoma …
(PSMA) is gaining importance in the treatment of patients with advanced prostate carcinoma …
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy
Purpose Although treatment planning and individualized dose application for emerging
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are …
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are …
The current landscape of prostate-specific membrane antigen (psma) imaging biomarkers for aggressive prostate cancer
H Al Saffar, DC Chen, C Delgado, J Ingvar, MS Hofman… - Cancers, 2024 - mdpi.com
Simple Summary The review explores the critical role of prostate-specific membrane antigen
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …
Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival …
S Moazemi, A Erle, S Lütje, FC Gaertner, M Essler… - Diagnostics, 2021 - mdpi.com
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed
tomography (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate …
tomography (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate …
Early molecular imaging response assessment based on determination of total viable tumor burden in [68 Ga] Ga-PSMA-11 PET/CT independently predicts overall …
F Rosar, F Wenner, F Khreish, S Dewes… - European Journal of …, 2022 - Springer
Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC) treated
with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the …
with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the …
Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis
W Roll, P Schindler, M Masthoff, R Seifert, K Schlack… - Cancers, 2021 - mdpi.com
Simple Summary PSMA Therapy has recently become an additional therapeutic option in
advanced prostate cancer. In the present study, the predictive and prognostic value of …
advanced prostate cancer. In the present study, the predictive and prognostic value of …
Voxel-wise prediction of post-therapy dosimetry for 177Lu-PSMA I&T therapy using deep learning
1424 Introduction: PSMA-directed radioligand therapy (RLT) has become one of the
effective treatment options for metastatic castration-resistant prostate cancer (mCRPC) …
effective treatment options for metastatic castration-resistant prostate cancer (mCRPC) …
Assessing response to 177Lu-PSMA radioligand therapy using modified PSMA PET progression criteria
K Michalski, C Klein, T Brüggemann… - Journal of Nuclear …, 2021 - Soc Nuclear Med
PET/CT targeting the prostate-specific membrane antigen (PSMA) plays a key role in staging
of patients with prostate cancer. Moreover, it is used not only for the assessment of adequate …
of patients with prostate cancer. Moreover, it is used not only for the assessment of adequate …
Psma pet/ct for response assessment of 177lu-psma therapy
PE Hartrampf, SE Serfling, K Michalski, AK Buck… - Seminars in Nuclear …, 2024 - Elsevier
Prostate-specific membrane antigen (PSMA) PET/CT has been widely integrated into the
management of prostate cancer (PCa) patients with biochemical recurrence, is increasingly …
management of prostate cancer (PCa) patients with biochemical recurrence, is increasingly …
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate …
V Prasad, K Huang, S Prasad, MR Makowski… - Frontiers in …, 2021 - frontiersin.org
Background Prostate-specific membrane antigen (PSMA) targeting radioligands have
transformed treatment of prostate cancer. Radioligand therapy (RLT) with 177Lu-PSMA in …
transformed treatment of prostate cancer. Radioligand therapy (RLT) with 177Lu-PSMA in …
相关搜索
- 177lu psma prostate cancer
- 177lu psma radioligand therapy
- 177lu psma machine learning
- 177lu psma clinical parameters
- 177lu psma pet ct
- machine learning clinical parameters
- decision support clinical parameters
- machine learning decision support
- 177lu psma decision support
- 177lu psma high accuracy
- high accuracy clinical parameters
- machine learning high accuracy
- high accuracy decision support
- 177lu psma radiomics features
- pet ct radiomics features
- machine learning prostate cancer